SCHEMBL3079812

SCHEMBL3079812

CC(=O)C(Cc1ccc(C(=O)c2ccccc2)cc1)C(=O)Cc1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MDM2 Q00987 1/20 0.50
SRD5A2 P31213 3/20 0.46
ALDH1A1 P00352 4/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
HTT P42858 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
PPARG P37231 3/20 0.43
PPARA Q07869 2/20 0.43
PPARD Q03181 1/20 0.43
LMNA P02545 1/20 0.42
ELANE P08246 1/20 0.41
ATM Q13315 1/20 0.40
ALPI P09923 1/20 0.40
PKM P14618 1/20 0.40
PTGS1 P23219 1/20 0.40
XIAP P98170 1/20 0.40
SLC7A5 Q01650 1/20 0.40
MAPT P10636 1/20 0.40
ACHE P22303 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3087342 0.89 MDM2 (0.52) MDM2ALPIPKMPTGS1XIAP
SCHEMBL3091602 0.88 MDM2 (0.55) MDM2SRD5A2ALDH1A1L3MBTL1HTT
SCHEMBL13148575 0.83 MDM2 (0.64) MDM2SRD5A2ALDH1A1L3MBTL1HTT
SCHEMBL15391739 0.79 MDM2 (0.60) MDM2SRD5A2ALDH1A1L3MBTL1HTT
SCHEMBL1896075 0.77 MDM2 (0.61) MDM2LMNAALPIPKMPTGS1
SCHEMBL16728148 0.76 SLC7A5 (0.55) MDM2SRD5A2ALDH1A1L3MBTL1HTT
SCHEMBL9242408 0.76 MDM2 (0.79) MDM2ALDH1A1L3MBTL1PPARGPPARA
SCHEMBL14263733 0.76 MDM2 (0.52) MDM2LMNAALPIPKMPTGS1
SCHEMBL28141057 0.76 MDM2 (0.52) MDM2LMNAALPIPKMPTGS1
SCHEMBL16162416 0.76 ALDH1A1 (0.56) SRD5A2ALDH1A1L3MBTL1HTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2203496-B1 PHOTOLATENT CATALYSTS BASED ON ORGANOMETALLIC COMPOUNDS BASF SE (DE) 2018-04-11 EP disclosed
US-8318830-B2 Photolatent catalysts based on organometallic compounds BASF SE (DE) 2012-11-27 US disclosed
US-20100234485-A1 PHOTOLATENT CATALYSTS BASED ON ORGANOMETALLIC COMPOUNDS BASF SE (DE) 2010-09-16 US disclosed
EP-2203496-A1 PHOTOLATENT CATALYSTS BASED ON ORGANOMETALLIC COMPOUNDS BASF SE (DE) 2010-07-07 EP disclosed
WO-2009050115-A1 PHOTOLATENT CATALYSTS BASED ON ORGANOMETALLIC COMPOUNDS BASF SE (CH) 2009-04-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234485-A1 PHOTOLATENT CATALYSTS BASED ON ORGANOMETALLIC COMPOUNDS PUF60, TST, MPST MDM2 3500/4885SRD5A2 4506/4885ALDH1A1 1432/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.